Date
14 November 2026
Access to medicines: innovations not reaching those in need
In an article for The Lancet, Udani Samarasekera examines findings from the 2026 Access to Medicine Index, highlighting progress in pharmaceutical companies’ access planning alongside persistent gaps in affordability, availability and patient reach in low- and middle-income countries.Â
The article notes that access plans now cover 69% of late-stage products in development, more than three times the proportion in 2018. However, it highlights that many plans for non-communicable diseases focus primarily on product registration, without addressing whether patients will be able to afford or obtain treatment. It also reports declining company engagement in research and development for priority disease areas, including communicable and neglected tropical diseases.Â
The article explores access challenges across several therapeutic areas, including limited access to GLP-1 medicines and insulin, the uneven geographic coverage of cancer medicines, and the exclusion of some middle-income countries from voluntary licensing agreements for long-acting HIV prevention medicines. It also considers how trade policies could affect pharmaceutical supply chains, pricing and companies’ willingness to serve lower-price markets. While some experts welcome the growing integration of access into company strategies, others question whether this is translating into meaningful change for patients and call for stronger action from governments.
Moy Bracken, Head of the Research Unit at the Access to Medicine Foundation, is quoted highlighting the gap between companies’ growing focus on access planning and the impact this has for patients. She also raises the issue of declining industry investment in research and development for priority health needs: "We are at the lowest level since before 2018, [which is concerning because] we need new innovation for mostly infectious diseases that don't have optimum therapies, and secondly because many of these communicable diseases could be global health security threats in the future."